Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer
Xenetic Biosciences to Present at Biotech Showcase 2017
Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer
Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference
Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast
Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors
Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update
Xenetic Biosciences Announces the Closing of its $10M Public Offering
